Does Victoza cause yeast infections? This is a common concern amongst patients prescribed liraglutide for type 2 diabetes. Whilst yeast infections (thrush) occur more frequently in people with diabetes, there is no established direct causal link between Victoza and fungal infections in UK regulatory guidance or the Summary of Product Characteristics. The increased risk of candidiasis in diabetes primarily relates to elevated blood glucose levels rather than specific medications. Understanding this distinction helps patients manage their condition effectively whilst benefiting from improved glycaemic control with GLP-1 receptor agonists like Victoza.
Quick Answer: Victoza (liraglutide) does not directly cause yeast infections; the increased thrush risk in diabetes relates primarily to elevated blood glucose rather than the medication itself.
Victoza (liraglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus. It is administered as a once-daily subcutaneous injection and works by mimicking the action of naturally occurring GLP-1, a hormone released by the intestine in response to food intake.
The primary mechanism of action involves several complementary pathways. Victoza enhances glucose-dependent insulin secretion from pancreatic beta cells, meaning it stimulates insulin release only when blood glucose levels are elevated. This reduces the risk of hypoglycaemia compared to some other diabetes medications, although this risk increases when used in combination with sulfonylureas or insulin. Additionally, it suppresses inappropriate glucagon secretion from pancreatic alpha cells, which helps prevent the liver from releasing excess glucose into the bloodstream. Victoza also slows gastric emptying, prolonging the sensation of fullness and contributing to modest weight loss in many patients.
According to NICE guidance (NG28), GLP-1 receptor agonists like Victoza are typically considered for adults with type 2 diabetes when metformin and other oral therapies have not achieved adequate glycaemic control. NICE recommends considering GLP-1 therapy in people with BMI ≥35 kg/m² (or lower if weight-related comorbidities are present), or when insulin would be the next option but weight gain would be problematic. Continuation criteria include achieving a reduction of at least 11 mmol/mol (1.0%) in HbA1c and weight loss of at least 3% at 6 months. The medication has demonstrated efficacy in reducing HbA1c levels by approximately 11-16 mmol/mol (1.0–1.5%) in clinical trials.
Whilst Victoza is generally well-tolerated, patients may experience gastrointestinal side effects such as nausea, vomiting, and diarrhoea, particularly during the initial titration period. Patients with diabetes have an inherently higher risk of certain infections, including yeast infections, primarily due to elevated blood glucose levels rather than as a direct medication effect.
Mounjaro® is the most innovative GLP-1 medication proven to dramatically curb appetite, hunger, and cravings to help professional men achieve substantial weight loss.
Start Here
Wegovy® is a weekly injectable GLP-1 medication with proven effectiveness in reducing appetite, hunger, and cravings to help busy professionals lose significant weight.
Start HereThe relationship between diabetes and yeast infections is well-established, but there is no direct causal link between Victoza and fungal infections in the Summary of Product Characteristics (SmPC) or major regulatory guidance. Understanding the underlying mechanisms of increased infection risk in diabetes is important for patients taking any diabetes medication, including Victoza.
Primarily, patients with type 2 diabetes face elevated infection risk due to hyperglycaemia. High blood glucose levels create a favourable environment for Candida species to proliferate, as glucose is present in higher concentrations in bodily fluids, including urine and genital secretions. Whilst Victoza improves glycaemic control overall, fluctuations during treatment initiation or periods of suboptimal control may still permit fungal overgrowth.
Secondly, urinary glucose excretion may play a role. Unlike SGLT2 inhibitors (which have a well-established association with genital mycotic infections due to increased urinary glucose excretion), Victoza does not directly increase glucosuria. However, some patients may experience transient glucosuria during periods of poor diabetes control. This creates a nutrient-rich environment in the urogenital area conducive to yeast colonisation.
Additionally, other factors that increase thrush risk in people with diabetes include immune system alterations, changes in local pH, and microvascular complications affecting tissue perfusion and local immunity. These factors exist independently of medication choice.
It is important to note that while patient reports occasionally mention yeast infections during GLP-1 therapy, causality has not been established. Healthcare professionals should maintain awareness of the general increased risk of fungal infections in diabetes whilst recognising that improving glycaemic control with medications like Victoza may actually help reduce this risk over time. Patients with pre-existing risk factors—such as obesity, immunosuppression, antibiotic use, or poor glycaemic control—may be more vulnerable to yeast infections regardless of their specific diabetes therapy.
Genital candidiasis (thrush) is the most common form of yeast infection that may affect people with diabetes. In women, typical symptoms include:
Vulvovaginal itching and irritation
Thick, white, cottage cheese-like vaginal discharge (usually odourless)
Soreness, redness, or swelling of the vulva
Discomfort during sexual intercourse (dyspareunia)
Stinging or burning during urination (dysuria)
In men, genital candidiasis (balanitis) may present with:
Redness, irritation, or inflammation of the glans penis
Itching or burning sensation under the foreskin
White discharge or difficulty retracting the foreskin
Unpleasant odour
Oral thrush (oropharyngeal candidiasis) is less commonly associated with diabetes but may occur in immunocompromised individuals. Signs include white patches on the tongue or inner cheeks, soreness, and difficulty swallowing.
Management approaches for uncomplicated yeast infections typically involve:
First-line treatment consists of topical antifungal preparations such as clotrimazole pessaries or cream (available over-the-counter in UK pharmacies). Oral fluconazole 150mg as a single dose is available from pharmacies for uncomplicated vaginal candidiasis in women aged 16-60 years and for candidal balanitis in men aged 16-60 years who have previously been diagnosed by a doctor. Pharmacists will assess suitability, and fluconazole should be avoided in pregnancy, liver disease, and with certain medications (including warfarin and some statins). Most uncomplicated cases show improvement within 2-3 days and resolve within 7 days of treatment.
Preventive measures are equally important:
Optimise glycaemic control—maintaining HbA1c within target range reduces infection susceptibility
Maintain good hygiene—gentle washing with water, avoiding perfumed products
Wear breathable cotton underwear and avoid tight-fitting clothing
Avoid unnecessary antibiotic use, which disrupts normal bacterial flora
Patients should not discontinue Victoza without medical consultation if they develop a yeast infection, as the benefits of glycaemic control typically outweigh this manageable condition. If infections become recurrent (four or more episodes in 12 months), further investigation and specialist referral may be warranted.
Whilst most yeast infections are uncomplicated and respond well to over-the-counter treatment, certain circumstances require prompt medical evaluation. Patients taking Victoza should contact their GP or diabetes specialist nurse if they experience:
Recurrent or persistent infections—if yeast infections occur frequently (four or more episodes within 12 months) or fail to resolve with standard antifungal treatment, underlying causes must be investigated. This may indicate suboptimal diabetes control, immunosuppression, or resistant Candida species requiring alternative therapy.
Severe or worsening symptoms—including extensive inflammation, ulceration, bleeding, or systemic symptoms such as fever, which may suggest complicated infection or alternative diagnoses such as bacterial vaginosis, sexually transmitted infections, or dermatological conditions.
First-time symptoms in men—male genital candidiasis warrants medical assessment to exclude other conditions and ensure appropriate treatment, particularly if symptoms are severe or accompanied by urinary symptoms.
Pregnancy or breastfeeding—treatment options differ in these circumstances, and Victoza is not recommended during pregnancy. If pregnancy occurs while using Victoza, it should be discontinued. Women should use topical clotrimazole rather than oral fluconazole for thrush during pregnancy and discuss diabetes management with their healthcare team.
Immunocompromised status—patients with HIV, those receiving immunosuppressive therapy, or individuals with other conditions affecting immune function require specialist assessment, as they face higher risk of invasive or disseminated fungal infection.
Concerns about diabetes control—if yeast infections coincide with symptoms of hyperglycaemia (increased thirst, frequent urination, fatigue, blurred vision), patients should check their blood glucose levels and contact their diabetes team. Dose adjustment of Victoza or other diabetes medications may be necessary.
Medication review—patients experiencing troublesome recurrent infections should request a comprehensive medication review. Whilst discontinuing Victoza is rarely necessary, alternative GLP-1 preparations or different therapeutic classes may be considered if infections significantly impact quality of life.
The NHS 111 service provides 24-hour advice for non-emergency concerns, whilst urgent care or A&E attendance is appropriate if severe systemic symptoms develop. Patients should report any suspected adverse reactions to medications, including Victoza, through the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk). Maintaining open communication with healthcare providers ensures optimal management of both diabetes and any associated complications.
No, there is no established direct causal link between Victoza and yeast infections in UK regulatory guidance. The increased risk of thrush in diabetes relates primarily to elevated blood glucose levels rather than the medication itself.
No, do not discontinue Victoza without medical consultation. Yeast infections are typically manageable with antifungal treatment, and maintaining good glycaemic control with Victoza may actually reduce long-term infection risk.
Seek medical advice if infections recur frequently (four or more times in 12 months), fail to respond to standard treatment, are accompanied by severe symptoms or fever, or if you are pregnant, immunocompromised, or experiencing signs of poor diabetes control.
All medical content on this blog is created based on reputable, evidence-based sources and reviewed regularly for accuracy and relevance. While we strive to keep content up to date with the latest research and clinical guidelines, it is intended for general informational purposes only.
DisclaimerThis content is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional with any medical questions or concerns. Use of the information is at your own risk, and we are not responsible for any consequences resulting from its use.
